154 related articles for article (PubMed ID: 29581773)
1. Epigenetic modification of
Misawa K; Misawa Y; Imai A; Mochizuki D; Endo S; Mima M; Ishikawa R; Kawasaki H; Yamatodani T; Kanazawa T
J Cancer; 2018; 9(6):941-949. PubMed ID: 29581773
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic silencing of
Misawa K; Mochizuki D; Imai A; Misawa Y; Endo S; Mima M; Kawasaki H; Carey TE; Kanazawa T
Clin Epigenetics; 2017; 9():64. PubMed ID: 28616099
[TBL] [Abstract][Full Text] [Related]
3. Aberrant methylation inactivates somatostatin and somatostatin receptor type 1 in head and neck squamous cell carcinoma.
Misawa K; Misawa Y; Kondo H; Mochizuki D; Imai A; Fukushima H; Uehara T; Kanazawa T; Mineta H
PLoS One; 2015; 10(3):e0118588. PubMed ID: 25734919
[TBL] [Abstract][Full Text] [Related]
4.
Imai A; Mochizuki D; Misawa Y; Nakagawa T; Endo S; Mima M; Yamada S; Kawasaki H; Kanazawa T; Misawa K
DNA Cell Biol; 2019 Jul; 38(7):678-687. PubMed ID: 31188017
[TBL] [Abstract][Full Text] [Related]
5. Frequent promoter hypermethylation of tachykinin-1 and tachykinin receptor type 1 is a potential biomarker for head and neck cancer.
Misawa K; Kanazawa T; Misawa Y; Imai A; Uehara T; Mochizuki D; Endo S; Takahashi G; Mineta H
J Cancer Res Clin Oncol; 2013 May; 139(5):879-89. PubMed ID: 23420374
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic inactivation of galanin and GALR1/2 is associated with early recurrence in head and neck cancer.
Misawa K; Misawa Y; Kanazawa T; Mochizuki D; Imai A; Endo S; Carey TE; Mineta H
Clin Exp Metastasis; 2016 Feb; 33(2):187-95. PubMed ID: 26572146
[TBL] [Abstract][Full Text] [Related]
7. Tumor suppressor activity and inactivation of galanin receptor type 2 by aberrant promoter methylation in head and neck cancer.
Misawa Y; Misawa K; Kanazawa T; Uehara T; Endo S; Mochizuki D; Yamatodani T; Carey TE; Mineta H
Cancer; 2014 Jan; 120(2):205-13. PubMed ID: 24122450
[TBL] [Abstract][Full Text] [Related]
8. Hypermethylation of collagen α2 (I) gene (COL1A2) is an independent predictor of survival in head and neck cancer.
Misawa K; Kanazawa T; Misawa Y; Imai A; Endo S; Hakamada K; Mineta H
Cancer Biomark; 2011-2012; 10(3-4):135-44. PubMed ID: 22674299
[TBL] [Abstract][Full Text] [Related]
9. Genes Located on 18q23 Are Epigenetic Markers and Have Prognostic Significance for Patients with Head and Neck Cancer.
Misawa K; Kanazawa T; Mochizuki D; Imai A; Mima M; Yamada S; Morita K; Misawa Y; Shinmura K; Mineta H
Cancers (Basel); 2019 Mar; 11(3):. PubMed ID: 30901947
[TBL] [Abstract][Full Text] [Related]
10. Site-specific methylation patterns of the GAL and GALR1/2 genes in head and neck cancer: Potential utility as biomarkers for prognosis.
Misawa K; Mochizuki D; Endo S; Mima M; Misawa Y; Imai A; Shinmura K; Kanazawa T; Carey TE; Mineta H
Mol Carcinog; 2017 Mar; 56(3):1107-1116. PubMed ID: 27685843
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of epigenetic inactivation of vascular endothelial growth factor receptors in head and neck squamous cell carcinoma.
Misawa Y; Misawa K; Kawasaki H; Imai A; Mochizuki D; Ishikawa R; Endo S; Mima M; Kanazawa T; Iwashita T; Mineta H
Tumour Biol; 2017 Jul; 39(7):1010428317711657. PubMed ID: 28718364
[TBL] [Abstract][Full Text] [Related]
12. Promoter methylation of TIMP3 and CDH1 predicts better outcome in head and neck squamous cell carcinoma treated by radiotherapy only.
De Schutter H; Geeraerts H; Verbeken E; Nuyts S
Oncol Rep; 2009 Feb; 21(2):507-13. PubMed ID: 19148529
[TBL] [Abstract][Full Text] [Related]
13. The association, clinicopathological significance, and diagnostic value of
Shen Z; Zhou C; Li J; Deng H; Li Q; Wang J
Onco Targets Ther; 2016; 9():6763-6773. PubMed ID: 27826202
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of aberrant promoter hypermethylation of tumor-related genes in early-stage head and neck cancer.
Misawa K; Mochizuki D; Imai A; Endo S; Mima M; Misawa Y; Kanazawa T; Carey TE; Mineta H
Oncotarget; 2016 May; 7(18):26087-98. PubMed ID: 27027429
[TBL] [Abstract][Full Text] [Related]
15. Association of TET3 epigenetic inactivation with head and neck cancer.
Misawa K; Imai A; Mochizuki D; Mima M; Endo S; Misawa Y; Kanazawa T; Mineta H
Oncotarget; 2018 May; 9(36):24480-24493. PubMed ID: 29849955
[TBL] [Abstract][Full Text] [Related]
16. Galanin has tumor suppressor activity and is frequently inactivated by aberrant promoter methylation in head and neck cancer.
Misawa K; Kanazawa T; Misawa Y; Uehara T; Imai A; Takahashi G; Takebayashi S; Cole A; Carey TE; Mineta H
Transl Oncol; 2013 Jun; 6(3):338-46. PubMed ID: 23730414
[TBL] [Abstract][Full Text] [Related]
17. The neuropeptide genes
Misawa K; Mima M; Imai A; Mochizuki D; Misawa Y; Endo S; Ishikawa R; Kanazawa T; Mineta H
Clin Epigenetics; 2018; 10():52. PubMed ID: 29682090
[TBL] [Abstract][Full Text] [Related]
18. Positive correlation of tissue inhibitor of metalloproteinase-3 and death-associated protein kinase hypermethylation in head and neck squamous cell carcinoma.
Nayak CS; Carvalho AL; Jeronimo C; Henrique R; Kim MM; Hoque MO; Chang S; Jiang WW; Koch W; Westra W; Sidransky D; Califano J
Laryngoscope; 2007 Aug; 117(8):1376-80. PubMed ID: 17592394
[TBL] [Abstract][Full Text] [Related]
19.
Sailer V; Holmes EE; Gevensleben H; Goltz D; Dröge F; Franzen A; Dietrich J; Kristiansen G; Bootz F; Schröck A; Dietrich D
Clin Epigenetics; 2017; 9():12. PubMed ID: 28174607
[TBL] [Abstract][Full Text] [Related]
20. The Association and Clinical Significance of CDKN2A Promoter Methylation in Head and Neck Squamous Cell Carcinoma: a Meta-Analysis.
Zhou C; Shen Z; Ye D; Li Q; Deng H; Liu H; Li J
Cell Physiol Biochem; 2018; 50(3):868-882. PubMed ID: 30355925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
